The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
- Background: The epidermal growth factor receptor (EGFR) is a potential target of anticancer therapy in gastric cancer. However, its prognostic role in metastatic gastric or gastroesophageal junction (GE) cancer has not been established yet. Methods: EGFR status was analyzed by immunohistochemistry (IHC) in paraffin-embedded samples from 357 patients who received chemotherapy in 4 first-line trials. Automated RNA extraction from paraffin and RT-quantitative PCR were additionally used to evaluate EGFR mRNA expression in 130 patients. Results: EGFR protein expression (any grade) and overexpression (3+) were observed in 43% and 11% of patients, respectively. EGFR positivity correlated with intestinal type histology (p = 0.05), but not with other clinicopathologic characteristics. Median follow-up was 18.2 months. Median overall survival (OS) was similar in patients with EGFR positive vs. those with EGFR negative tumors, regardless whether positivity was defined as ≥1+ (10.6 vs. 10.9 months, p = 0.463) or as 3+ (8.6 vs. 10.8 months, p = 0.377). The multivariate analysis indicated that EGFR status is not an independent prognostic factor (hazard ratio 0.85, 0.56 to 1.12, p = 0.247). There were also no significant differences in overall survival when patients were categorized according to median (p = 0.116) or quartile (p = 0.767) distribution of EGFR mRNA gene expression. Similar distributions of progression-free survival according to EGFR status were observed. Conclusions: Unlike different cancer types where EGFR-positive disease is associated with an adverse prognostic value, EGFR positivity is not prognostic of patient outcome in metastatic gastric or GE cancer.
Verfasserangaben: | Akin Atmaca, Dominique Werner, Claudia PauligkGND, Kristina Steinmetz, Ralph Wirtz, Hans-Michael Altmannsberger, Elke Jäger, Salah-Eddin al- BatranORCiDGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-372899 |
DOI: | https://doi.org/10.1186/1471-2407-12-524 |
ISSN: | 1471-2407 |
Pubmed-Id: | https://pubmed.ncbi.nlm.nih.gov/23153332 |
Titel des übergeordneten Werkes (Englisch): | BMC cancer |
Verlag: | BioMed Central |
Verlagsort: | London |
Dokumentart: | Wissenschaftlicher Artikel |
Sprache: | Englisch |
Datum der Veröffentlichung (online): | 15.11.2012 |
Datum der Erstveröffentlichung: | 15.11.2012 |
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Datum der Freischaltung: | 22.04.2015 |
Freies Schlagwort / Tag: | EGFR Gastric cancer; Immunohistochemistry; Prognostic; Survival |
Jahrgang: | 12 |
Ausgabe / Heft: | 524 |
Seitenzahl: | 7 |
Bemerkung: | Copyright ©2012 Atmaca et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
HeBIS-PPN: | 369088514 |
Institute: | Medizin / Medizin |
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Lizenz (Deutsch): | Creative Commons - Namensnennung 2.0 |